Positive results in TACTI-003 for 1L HNSCC cohort B patients
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The combination of eftilagimod alfa and KEYTRUDA achieved a notable response rate and a high complete response rate among evaluable patients. The treatment demonstrated durability, with over half of the patients receiving therapy for at least six months and no new safety signals observed. Immutep plans to discuss the promising results with regulatory agencies due to the high unmet medical need in this patient population.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Immutep
- Webcast slides for new Efti clinical data in 1st line HNSCC
- Positive topline results from ph2b in head & neck cancer
- Immutep completes underwritten retail entitlement offer
- Immutep completes institutional pro-rata offer & placement
- Immutep announces Ph 3 clinical trial collaboration with MSD
Later from Immutep
- Webcast to discuss data presented at ESMO Plenary Session
- Regulatory Clearance received for Phase 1 trial of IMP761
- Successful Meeting with FDA on Phase III Design in NSCLC
- First Participant Dosed in Phase I Study of IMP761
- TACTI-003 data selected for oral presentation at ESMO 2024
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep